NewAmsterdam Pharma Company N.V. announced the appointment of Juliette Audet as Chief Business Officer and her simultaneous resignation from the Company?s Board of Directors, both effective April 1, 2024. Ms. Audet is a seasoned life sciences executive and investor with extensive pharmaceutical business development, finance and operational expertise. She was most recently a Partner at Forbion, where she was part of the team that built NewAmsterdam Pharma, and played a key role in out licensing obicetrapib, setting up operations and recruiting the management team.

Prior to joining Forbion, Ms. Audet was a principal at the Novartis Venture Fund based in Cambridge, MA. She also worked at Novartis AG for their commercial division and at McKinsey and Company focusing on Pharma and Biotech. She earned her M.B.A. with distinction from Harvard Business School and her M.Sc.

in Physics from EPFL (Lausanne, Swiss Federal Institute of Technology).